Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 315-322, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rauch, F.
Right arrow Articles by Schoenau, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rauch, F.
Right arrow Articles by Schoenau, E.
Related Collections
Right arrow General Clinical Chemistry
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2002;48:315-322.)
© 2002 American Association for Clinical Chemistry, Inc.

Collagen Markers Deoxypyridinoline and Hydroxylysine Glycosides: Pediatric Reference Data and Use for Growth Prediction in Growth Hormone-deficient Children

Frank Rauch1a, Mareile Georg1, Angelika Stabrey1, Christina Neu1,2, Werner F. Blum3, Thomas Remer2, Friedrich Manz2 and Eckhard Schoenau1

1 Children’s Hospital, University of Cologne, Josef-Stelzmann Strasse 9, 50924 Cologne, Germany.

2 Research Institute for Child Nutrition, Heinstück 11, 44225 Dortmund, Germany.

3 Children’s Hospital, University of Giessen, Germany and Lilly Deutschland GmbH, Saalburgstrasse 153, 61350 Bad Homburg, Germany.

aAddress correspondence to this author at: Genetics Unit, Shriners Hospital for Children, 1529 Cedar Ave., Montreal, Qc H3G 1A6 Canada. Fax 1-514-8425581; e-mail frauch{at}shriners.mcgill.ca.

Background: In children and adolescents, markers of bone and collagen metabolism reflect the dynamics of skeletal growth and development. The aim of this study was to assess the relationship of the urinary collagen markers deoxypyridinoline (DPD) and hydroxylysine (Hyl) and its glycosides [galactosyl-Hyl (Gal-Hyl) and glucosyl-Gal-Hyl] with growth.

Methods: Urine samples from 240 apparently healthy children and adolescents (6–19 years; 124 girls) and from 51 prepubertal children with growth hormone (GH) deficiency (3–14 years; 14 girls) were analyzed. Urinary Hyl and its glycosides were quantified by HPLC, and DPD was assessed by chemiluminescence assay. Urinary concentrations of all markers were related to urinary creatinine.

Results: Multiple regression analysis revealed that only age and height velocity were independently associated with these markers in healthy children. In GH-deficient patients, the urinary excretion of both analytes after 4 weeks of GH therapy correlated significantly with the height increase during the first treatment year (r = 0.79 for Gal-Hyl; r = 0.70 for DPD; P <0.001 each). In a multivariate linear regression model using Gal-Hyl concentrations at 4 weeks, baseline concentrations of insulin-like growth factor 1 and height velocity after 3 months accounted for 80% of the variability in height gain during the first treatment year. A model using DPD concentrations at 4 weeks, in place of Gal-Hyl concentrations, as well as baseline concentrations of insulin-like growth factor 1 and height velocity after 3 months accounted for 83% of the variability.

Conclusions: These urinary bone and collagen markers give some early indication of growth response, but the prediction of an individual marker is too imprecise to serve as a basis for clinical decisions. Markers of bone and collagen metabolism might be more useful as components of multivariate growth prediction models.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
M. E. Kraenzlin, C. A. Kraenzlin, C. Meier, C. Giunta, and B. Steinmann
Automated HPLC Assay for Urinary Collagen Cross-links: Effect of Age, Menopause, and Metabolic Bone Diseases
Clin. Chem., September 1, 2008; 54(9): 1546 - 1553.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Rauchenzauner, A. Schmid, P. Heinz-Erian, K. Kapelari, G. Falkensammer, A. Griesmacher, G. Finkenstedt, and W. Hogler
Sex- and Age-Specific Reference Curves for Serum Markers of Bone Turnover in Healthy Children from 2 Months to 18 Years
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 443 - 449.
[Abstract] [Full Text] [PDF]

Home page
 J Bone Joint Surg BrHome page
B. Westhoff, R. Krauspe, A. E. Kalke, D. Hermsen, B. Kowall, R. Willers, and U. Schneider
Urinary excretion of deoxypyridinoline in Perthes' disease: A PROSPECTIVE, CONTROLLED COMPARATIVE STUDY IN 83 CHILDREN
J Bone Joint Surg Br, July 1, 2006; 88-B(7): 967 - 971.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
C Land, W F Blum, A Stabrey, and E Schoenau
Seasonality of growth response to GH therapy in prepubertal children with idiopathic growth hormone deficiency
Eur. J. Endocrinol., May 1, 2005; 152(5): 727 - 733.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.